Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...
MD Anderson Cancer Center is one of the world's most respected centers ... Baylor College of Medicine students, residents and fellows have opportunities for clinical rotations and research training at ...
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...
The University of Texas MD Anderson Cancer Center plans to further expand ... The facility will support pre-clinical research ...
6don MSN
Meetings designed to distribute grant money to fund research were canceled as part of a communications freeze at health ...
A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
He is joined by Robert Bresalier, M.D., professor of gastroenterology at The University of Texas MD Anderson Cancer Center ... groups of basic and clinical investigators, who constitute a growing and ...
HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today ...
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback